| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6183651 | Gynecologic Oncology | 2013 | 6 Pages |
Abstract
These results confirm our previous observation that clinical ovarian cancer includes a subset of tumors with sensitivity to estrogen pathway blockade. Expression profile of sensitive tumors appears to be detectably different from insensitive tumors, suggesting that further improvements in treatment efficacy can be obtained through appropriate patient selection.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Peter A. Argenta, Inhwa Um, Charlene Kay, David Harrison, Dana Faratian, Thanasak Sueblinvong, Melissa A. Geller, Simon P. Langdon,